269 related articles for article (PubMed ID: 21717445)
1. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
[TBL] [Abstract][Full Text] [Related]
2. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
3. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
[TBL] [Abstract][Full Text] [Related]
4. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
5. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
7. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
8. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
[TBL] [Abstract][Full Text] [Related]
10. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
[TBL] [Abstract][Full Text] [Related]
11. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
12. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
[TBL] [Abstract][Full Text] [Related]
13. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
14. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
18. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
[TBL] [Abstract][Full Text] [Related]
19. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
20. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]